Johnson & Johnson is proposing major changes to the way certain hospitals procure two of its biggest selling products under the 340B drug pricing program—but the federal government is pushing back.
J&J announced modifications on Friday to its 340B discount policy, noting that starting October 15, 2024, qualified hospitals can only obtain the pharma’s anti-inflammatory antibody Stelara (ustekinumab) and blood thinner Xarelto (rivaroxaban) through a rebate program. Under the plan, hospitals will first have to pay for the full price of the drugs and…
